The Loretta C. Ford Lifetime Achievement Award is presented annually by the National Nurse Practitioner Symposium to one individual that has demonstrated longevity, integrity, achievement and advocacy.
In addition to leveraging a pipeline of complex generics across its markets while focusing on OTC, Dr. Reddy's chairman K Satish Reddy said the branded generics would be one of the ways the company drives growth in the coming years.
In the aftermath of flooding in West Virginia, Fruth Pharmacy stepped with donations of sanitary necessities, toys for children, cleaning supplies, first aid kits and OTC medication to help those affected by the floods.
A new report from Transparency Market Research is highlighting the projected growth of the pharmacy automation industry, which it says will see a compound annual growth rate of 7.3% between 2012 and 2018.
Stansel has previously served as acting general counsel for the Dept. of Health and Human Services, working as the chief legal officer for it and several sub-agencies including the Food and Drug Administration.
Vaccine Complete identifies patients eligible for vaccination and includes outreach to patient groups that are recommended to receive certain vaccines, all while automating protocols with prescribers and meeting state reporting mandates.
Reuters is reporting that the FDA’s Arthritis Advisory Board has unanimously recommended Amgen’s biosimilar of AbbVie’s Humira, ABP 501. The panel said that the drug was similar in safety and effectiveness to Humira for rheumatoid arthritis and plaque psoriasis, and it recommended that the biosimilar should also be approved for Crohn’s disease in adults and ulcerative colitis. (Reuters)
Based on Medicare adherence numbers among diabetic patients, the IMS Institute estimates that complications from type 2 diabetes will cost about $100 billion annually in the United States, with $4 billion attributable to Medicare patients.
The move is aimed at Nichi-Iko becoming one of the top 10 global generics leaders, and the companies said acquiring Sagent will boost Nichi-Iko’s ability to commercialize its biosimilar pipeline and increase its presence in injectables.